CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
Betacoronavirus
/ physiology
COVID-19
Coronavirus Infections
/ epidemiology
Delivery of Health Care
/ methods
Hematologic Neoplasms
/ epidemiology
Humans
Immunotherapy, Adoptive
/ methods
Infection Control
/ methods
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
Preventive Health Services
/ methods
Receptors, Antigen, T-Cell
/ immunology
SARS-CoV-2
COVID-19
Chimeric antigen receptor T-cells
Cytokine release syndrome
Immunocompromised
Relapsed/refractory hematological malignancies
Journal
Current research in translational medicine
ISSN: 2452-3186
Titre abrégé: Curr Res Transl Med
Pays: France
ID NLM: 101681234
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
18
04
2020
revised:
29
05
2020
accepted:
19
06
2020
pubmed:
6
7
2020
medline:
4
9
2020
entrez:
5
7
2020
Statut:
ppublish
Résumé
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
Identifiants
pubmed: 32620465
pii: S2452-3186(20)30042-8
doi: 10.1016/j.retram.2020.06.003
pmc: PMC7321051
pii:
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-118Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Références
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
J Hematol Oncol. 2019 Jul 4;12(1):69
pubmed: 31272471
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):147-157
pubmed: 32391658
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet Haematol. 2020 Apr;7(4):e351-e352
pubmed: 32220344
Engineering (Beijing). 2021 Jan;7(1):11-13
pubmed: 32292628
Cancer Discov. 2016 Jun;6(6):664-79
pubmed: 27076371
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Hematol Oncol. 2018 Sep 24;11(1):121
pubmed: 30249264
Blood Adv. 2020 Apr 14;4(7):1307-1310
pubmed: 32243501
Leukemia. 2019 Dec;33(12):2767-2778
pubmed: 31690821
Lancet Oncol. 2020 Feb;21(2):e104-e116
pubmed: 32007196
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
J Allergy Clin Immunol Pract. 2020 May;8(5):1489-1491
pubmed: 32220575
Transfus Med Rev. 2020 Apr;34(2):75-80
pubmed: 32107119
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Bone Marrow Transplant. 2019 Nov;54(11):1868-1880
pubmed: 31092900
Zhonghua Xue Ye Xue Za Zhi. 2020 Apr 14;41(4):341-343
pubmed: 32149486
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Oncoimmunology. 2018 Aug 6;8(10):e1271857
pubmed: 31646067
Lancet Oncol. 2020 Mar;21(3):e168-e178
pubmed: 32135120
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Infez Med. 2020 Ahead of print Jun 1;28(2):153-165
pubmed: 32275257